GH Research (GHRS)
(Delayed Data from NSDQ)
$11.92 USD
-0.41 (-3.33%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $12.17 +0.25 (2.10%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
GHRS 11.92 -0.41(-3.33%)
Will GHRS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GHRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GHRS
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
GHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
New Strong Buy Stocks for October 25th
Other News for GHRS
Buy Rating Affirmed for GH Research Amid Positive GH001 Trial Progress and Unique Treatment Potential
GH Research PLC Shareholders Approve Board Resolutions
GH Research Engages Investors at Upcoming Conferences
Largest Clinical-Stage Biotech Drug Stocks Declined 6%
Largest Clinical-Stage BioTech Drug Stocks Declined 6%